<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229033</url>
  </required_header>
  <id_info>
    <org_study_id>GER-EP-001</org_study_id>
    <nct_id>NCT01229033</nct_id>
  </id_info>
  <brief_title>Ablating Atrial Tachycardias Occuring During Ablation of Complex Fractionated Electrograms in Persistent AF</brief_title>
  <acronym>ATTAC CFAE</acronym>
  <official_title>Ablating Atrial Tachycardias Occuring During Ablation of Complex Fractionated Electrograms in Persistent AF - ATTAC CFAE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klinik für Kardiologie, Klinikum Karlsruhe, Prof. Dr. C. Schmitt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catheter ablation has proven to be an effective treatment option in patients suffering from
      symptomatic persistent atrial fibrillation (AF). Catheter ablation consists of two major
      steps: (1) Isolation of pulmonary veins to abolish the trigger of atrial fibrillation and (2)
      modification of left atrial and eventually right atrial substrate by ablation of complex
      fractionated atrial electrograms (CFAE). CFAE are mainly found at the ostia of the pulmonary
      veins, around the left atrial appendage, at the mitral annulus and the septum.

      When ablating CFAE 40-65% of the patients show a regularization of AF to an atrial
      tachycardia (AT) that can be macro- or micro-reentrant (localized re-entry). Until now the
      significance of the AT is unclear.

      In the following study we examine the hypothesis that an ablation of AT occuring during CFAE
      ablation (group 1) significantly improves outcome defined as freedom of atrial arrhythmia (AF
      or AT) compared to patients that are cardioverted when AF has regularized to AT (group 2).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from atrial tachyarrhythmia</measure>
    <description>Documented freedom from atrial tachyarrhythmia (AF or AT) during follow-up after first ablation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural and safety data</measure>
    <description>Duration of left atrial procedure, time of ablation, time of radiation and radiation dose from randomization until the end of the procedure.
In case of recurrence, characteristic of predominant tachyarrhythmia (AF or AT).
Safety parameters (pericardial tamponade, thrombembolic complications).
Number of re-ablations.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Ablation</condition>
  <condition>Atrial Flutter</condition>
  <arm_group>
    <arm_group_label>Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ablation of atrial tachycardia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardioversion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cardioversion of atrial tachycardia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation</intervention_name>
    <description>Ablation of atrial tachycardia</description>
    <arm_group_label>Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardioversion</intervention_name>
    <description>Cardioversion of atrial tachycardia</description>
    <arm_group_label>Cardioversion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (&gt;=18 und &lt; 80 years) with symptomatic persistent AF (AF episode enduring at
             least 7 days) but are successfully convertable in sinus rhythm (SR).

          -  At least one unsuccessful attempt of antiarrhythmic drug (betablocker or class I oder
             III).

          -  Oral anticoagulation with phenprocoumone or warfarine for at least 4 weeks prior to
             ablation with weekly documented INR &gt; 2..

          -  Withdrawal of antiarrhythmic drugs at least 3 half times prior to ablation except
             amiodarone.

          -  Atrial tachycardia occurring during ablation of CFAE (defined as CL &gt; 200 msec und
             stable activation sequence).

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel Deisenhofer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clemens Jilek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2010</study_first_submitted>
  <study_first_submitted_qc>October 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <name_title>Isabel Deisenhofer, MD and Clemens Jilek, MD</name_title>
    <organization>Deutsches Herzzentrum München</organization>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>ablation</keyword>
  <keyword>atrial flutter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

